This article is mentioned in:

Introduction

Breast cancer is the most frequent type of cancer among women and is the second leading cause of cancer-associated mortality in the female population of the United States (1). In the last two decades, the prognosis of patients with breast cancer has improved due to lifestyle modification, early detection, prophylactic mastectomy and advanced therapies (2). However, the curative effects of conventional chemotherapeutic agents are not satisfactory, and certain patients with advanced-stage breast cancer exhibit resistance to existing chemotherapeutic drugs (3). The risk factors of breast cancer are multiple and complicated, and the molecular mechanisms underlying its pathogenesis remain to be elucidated. Therefore, there has been increasing interest in identifying alternative chemotherapeutic drugs with novel anticancer mechanisms.

Harmine (HM) is a β-carboline alkaloid that was originally isolated from seeds of Peganum harmala and Banisteriopsis caapi in 1847 (4). HM is widely distributed in various medicinal plants and has long been used in folk medicine in the Middle East and Asia (5). Studies have demonstrated that HM exhibits significant antitumor activities in vitro and in vivo (6), including inhibiting proliferation (6), migration (7) and invasion (8), promoting apoptosis (9) and preventing tumorigenesis. HM inhibits the growth of several types of cancer, including lung (10), gastric (9), breast (11) and hepatic cancer (12). It arrests the cell cycle at the G0/G1 phase (13) and decreases the cyclin-dependent kinase activity (14). HM induces autophagy and apoptosis through the protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and extracellular signal-regulated kinase (ERK)1/2 signaling pathways, increases the expression of pro-apoptotic factors, including P53, caspases 3/8/9, B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax), and BH3-interacting domain death agonist (Bid), and reduces the level of pro-inflammatory cytokines, including TNF-α, IL-6 and granulocyte-macrophage colony-stimulating factor, in melanoma and gastric cancer (7). HM induces autophagy via increasing LC3-II and downregulating P62 in a dose-dependent manner in B16 cells (15). It can also suppress the expression of pro-metastatic genes, including matrix metalloproteinase-9, ERK and vascular endothelial growth factors, to inhibit melanoma cell invasion (16).

Transcriptional co-activator with PDZ-binding motif (TAZ) was initially identified as a 14-3-3 binding protein (17). Due to the lack of a DNA-binding domain, TAZ is not a transcription factor, but it can function as a transcriptional regulator though its transactivation domain. In addition to its interaction with 14-3-3, it has been reported to interact with multiple proteins, including thyroid transcription factor-1 (18), myogenic differentiation 1 (19), Smads (20), core-binding factor α1/Runt-related transcription factor 2 (21), transcriptional enhancer factor-1 (22), peroxisome proliferator-activated receptor (23) and TEA domains (24). Serving as a transcriptional coactivator, TAZ is important in osteoblastic, myogenic and adipogenic differentiation (25). TAZ was initially identified as an oncogenic protein in non-small cell lung cancer in 2011 (26). Accumulating studies have confirmed that the expression of TAZ is elevated in various types of human cancer, including colorectal cancer (27), glioblastoma (28) and breast cancer (29,30). The overexpression of TAZ leads to cancer cell behavior, including, but not limited to, growth-factor-independent proliferation (31) and resistance to chemotherapeutics (32). It promotes epithelial-mesenchymal transition (30), cell proliferation, migration, invasion, tumorigenesis and tumor formation in xenograft models (33), suggesting an oncogenic role of TAZ in the development of human cancer. Studies have shown that TAZ knockdown in MCF7 and Hs578T cells inhibited cell migration and invasion. The knockdown of TAZ in MCF7 cells also suppressed cell growth in vitro and in vivo (34). These data suggest that TAZ promotes cell proliferation, migration and invasion in breast cancer.

Considering the crucial roles of TAZ in breast cancer, the present study hypothesized that HM induces anticancer activity in breast cancer through the regulation of TAZ. The present study first showed that HM inhibited proliferation and migration, and promoted apoptosis in breast cancer cell lines, confirming its anticancer activity. Subsequently, it was found that the overexpression of TAZ was able to rescue HM-induced cellular toxicity. The results of the present study showed that HM exerted anticancer activity through inhibiting the expression and activity of TAZ.

Materials and methods

Preparation and chemical analysis of HM

HM (Fig. 1) was separated from the seeds of Peganum nigellastrum Bunge by column chromatography on AB-8 Macroporous Resin eluted with gradient ethyl alcohol and water. Furthermore, HM was isolated by preparative high-performance liquid chromatography (Fig. S1). Structure identification and the purity (>98%) of this compound (Figs. S2-8) were identified by spectroscopic methods and compared with the reported spectral data.

Figure 1 Structure of harmine.

Cell culture and HM treatment

The MDA-MB-231 and MCF-7 human breast cancer cell lines were obtained from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). The cells were cultured in DMEM (cat. no. C11965500BT; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% FBS (cat. no. 10100154; Gibco; Thermo Fisher Scientific, Inc.) and 100 μg/ml streptomycin at 37°C in an incubator with 5% CO2. A 200-mM stock solution of HM was prepared in DMSO (cat. no. V900090; Merck KGaA, Darmstadt, Germany) and diluted in culture media as necessary, to achieve the final desired experimental concentrations.

Cell transfection

The pCMV6-TAZ expression vector and pCMV6-control vector were purchased from OriGene Technologies, Inc. (Rockville, MD, USA; cat. no. Rc204082). MDA-MB-231 and MCF-7 cells were cultured in 96-well plates at a density of 5×103 cells per well for 24 h at 37°C, and then transfected with pCMV6-TAZ or pCMV6-control using Lipofectamine 3000 (cat. no. L3000-015; Thermo Fisher Scientific, Inc.) for 2 days. The transfected cells were visualized using a fluorescence microscope.

CCK-8 assay

The cells were plated in 96-well plates at a density of 5×103 cells per well. Following 24 h of incubation, the cells were left untreated or treated with HM at 50, 100 or 150 μM for 24, 48 or 72 h, followed by the addition of 10 μl CCK-8 to each well. The absorbance was measured at 450 nm using EnSpire Multimode plate reader (PerkinElmer, Inc., Waltham, MA, USA). The optical density (OD) was calculated for cell viability assay. Cell viability (%) = OD (treated) / OD (control) ×100%.

Wound healing assay

Cell migration was measured using a wound healing assay. The MDA-MB-231 and MCF7 cells were cultured in 6-well plates. A clean pipette tip was used to inflict a ‘wound’ when cells formed a confluent monolayer, and the cultured cells in DMEM were supplemented with 2% FBS. The cells were left untreated or treated with HM at 50, 100 or 150 μM. Images of the wound margins were captured using an inverted light microscope (Olympus Corporation, Tokyo, Japan) formed 0 h at this time point. Following incubation for 24 h, images of the same region of cells were captured for measurement. The wound healing rate was calculated using the following formula: (average wound margin in 0 h - average wound margin in 24 h) / average wound margin in 0 h.

DAPI staining

The cells were left untreated or treated with HM at 50, 100 or 150 μM for 24 h, washed twice with phosphate buffer saline (PBS), fixed in methanol for 10 min and finally stained with DAPI (cat. no. C1002; Beyotime Institute of Biotechnology, Haimen, China) for 10 min at room temperature. Images were then captured by fluorescent microscopy (Olympus Corporation).

Flow cytometry

Cell apoptosis was analyzed using a PE Annexin V apoptosis detection kit І (cat. no. 559763; BD Biosciences, USA). The cells were seeded in 6-well plates with 50, 100 and 150 μM HM for 24 h, and stained according to the manufacturer's instructions. The apoptotic cells were immediately detected by a FACS Caliber II Sorter and the Cell Quest FACS system (BD Biosciences). Data were analyzed using FlowJo software (version 7.6.5; Tree Star, Inc., Ashland, OR, USA).

Western blotting

The cells were lysed in cell lysis buffer (cat. no. P0013B; Beyotime Institute of Biotechnology) and centrifuged (12,000 × g, 10 min, 4°C) to collect the supernatants following treatment with HM (50, 100 or 150 μM) for 24 h. The protein concentration was measured using a BCA Protein Assay kit (cat. no. CW0014S; CWBio, Beijing, China), and an equal quantity (20 μg per well) of protein was separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked using 5% nonfat skim milk for 1 h at room temperature and then incubated with primary antibodies overnight for 4°C. The primary antibodies included anti-TAZ (1:1,000; cat. no. 70148; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-Bax (1:1,000; cat. no. ab-32503; Abcam, Cambridge, MA, USA), anti-Bcl-2 (1:1,000; cat. no. ab-32124; Abcam), anti-Erk (1:500; cat. no. sc-514302; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-phosphorylated (p-)Erk (1:500; cat. no. sc-81492; Santa Cruz Biotechnology, Inc.), anti-Akt (1:500; cat. no. sc-24500; Santa Cruz Biotechnology, Inc.), anti-p-Akt (1:500; cat. no. sc-7985; Santa Cruz Biotechnology, Inc.) and anti-β-actin (1:1,000; cat. no. sc-47778; Santa Cruz Biotechnology, Inc.). Following washing with TBST three times, for 10 min each time, goat anti-rabbit IgG (1:10,000; cat. no. sc-2040; Santa Cruz Biotechnology, Inc.) or goat anti-mouse IgG antibody (1:10,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) conjugated with horseradish peroxidase was incubated for 1 h at room temperature. The protein bands were visualized using the enhanced ECL Select Western Blotting Detection Reagent (cat. no. RPN2235; GE Healthcare Life Sciences, Chalfont, UK).

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

Total RNA was extracted from untreated and treated cells using TRIzol reagent (cat. no. 15596018; Thermo Fisher Scientific, Inc.) and cDNA was synthesized using the ReverTra Ace qPCR RT kit (cat. no. FSQ-101; Toyobo Life Science, Osaka, Japan). The qPCR was performed using UltraSYBR mixture (cat. no. CW-2601; CWBio) on an ABI StepOne Plus QPCR system (Thermo Fisher Scientific, Inc.). The thermocycling steps were as follows: Initial denaturation at 95°C for 10min, followed by 40 cycles at 95°C for 15 sec, 58°C for 1 min, and a final extension step at 72°C for 5 min. The 2-ΔΔCq method was used to calculate changes in relative mRNA expression levels (35). The primer sequences used were as follows: TAZ, forward 5'-GTCACCAACAGTAGCTCAGATC-3' and reverse 5'-AGT GATTACAGCCAGGTTAGAAAG-3'; β-actin, forward 5'-AC TCTTCCAGCCTTCCTTCC-3' and reverse 5'-CGTCATACT CCTGCTTGCTG-3'.

Xenograft mice model

A total of 20 six-week-old male athymic nude BALB/c mice (weight, 16-18 g) purchased from Beijing Vital River Laboratory Animal Technology (Beijing, China) were housed under specific pathogen-free conditions (24-26°C; 12-h light/dark cycle; free access to food and water). The mice were subcutaneously inoculated with MCF-7 cells (1×107) resuspended in 0.1 ml DMEM. When the tumor size reached 100 mm3, the mice were randomly divided into four groups (n=5/group) to receive one of the following treatments: Normal saline (NS; intraperitoneal injection) or 20, 40 or 80 mg/kg/day of HM (5 days per week for 2 weeks, intraperitoneal injection). Tumor length (L) and width (W) were measured at 2-day intervals using a Vernier caliper, and tumor volume (V) was calculated using the following formula: V (mm3) = L (mm) × W2 (mm2) × 0.5. After 4 weeks injection, all mice were sacrificed and tumor tissues were removed. Each mouse bore a single tumor, the maximum diameter of a single subcutaneous tumor reached 15.98 mm, the maximum tumor volume reached 1,189 mm3. Tumor tissues from the mice were dissected for western blotting, RT-qPCR analysis and immunohistochemistry (IHC). The animal experiments were approved by the Committee on the Ethics of Animal Experiments of the Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China; IACUC no. 837).

IHC analysis

IHC was performed to detect the levels of TAZ, Bcl-2, Bax, p-Erk and p-Akt in mouse tumor tissues. The samples were embedded in paraffin and sliced into thin sections (5 μm). The sections were dewaxed in xylene and sequentially rehydrated with 100, 95, 80 and 75% ethanol. The slides were blocked with BSA for 2 h at room temperature. The slides were incubated with primary antibodies anti-TAZ, Bcl-2, Bax, p-Erk and p-Akt (1:200) overnight at 4°C. Following washing three times with PBS for 10 min each time, biotinylated goat anti-rabbit secondary antibody (1:200; cat. no. A0279; Beyotime Institute of Biotechnology) was incubated for 1 h at 37°C, and diaminobenzidine tetrachloride (cat. no. P0203; Beyotime Institute of Biotechnology) was used for staining at 37°C for 10 min. Data were analyzed using a light microscope (Olympus Corporation).

Statistical analysis

Statistical analysis was performed by Student's t-test for comparison between two groups or one-way ANOVA for comparison between more than two groups. The least-significant difference post hoc test was used following ANOVA. All statistical analyses were performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

HM inhibits proliferation and migration, and induces apoptosis in MDA-MB-231 and MCF-7 cells

The anti-proliferative effect of HM on breast cancer cells was evaluated via CCK-8 assay. The MDA-MB-231 and MCF-7 cells were treated with different concentrations of HM for 24, 48 and 72 h, respectively. As shown in Fig. 2A, HM inhibited cell proliferation in a dose- and time-dependent manner. In addition to inhibiting cell proliferation, HM suppressed the migration of breast cancer cells. The MDA-MB-231 and MCF-7 cells were exposed to different concentrations of HM for 24 h, as shown in Fig. 2B, and the results revealed a dose-dependent inhibition of cell migration. Apoptotic morphological changes were determined by DAPI staining. Chromatin condensation and nuclear fragmentation, which are characteristics of apoptosis, were evident in the MDA-MB-231 and MCF-7 cells treated with HM (50, 100 or 150 μM) for 24 h. As shown in Fig. 2C, a significant increase of chromatin condensation and nuclear fragmentation was observed in the HM-treated cells, when compared with that of control (no HM added) cells. To further confirm the pro-apoptotic effect of HM, cell apoptosis was determined by flow cytometry using a Annexin V apoptosis detection kit. Following treatment of the MDA-MB-231 cells with HM at 50, 100 or 150 μM for 24 h, the apoptotic population increased from 5.7 to 26.7% in a dose-dependent manner. Similar results were observed in MCF-7 cells (Fig. 2D). In combination, these results indicated that HM had an anticancer effect on the breast cancer cell lines.

Figure 2 HM inhibits proliferation and migration, and induces apoptosis of MDA-MB-231 and MCF-7 cells. (A) Dose- and time-dependent effects of HM on MDA-MB-231 and MCF-7 cell viability. Cells were treated with 50, 100 or 150 μM HM for 24, 48 and 72 h, and cell viability was measured via CCK-8 assay. Data are presented as the mean ± SD. (B) MDA-MB-231 and MCF-7 cells were treated with HM (50, 100 or 150 μM) for 24 h. Cell migration was detected using a monolayer wound healing assay (magnification, ×400). The wound healing rate at 24 h was quantified. (C) Apoptotic morphology of the MDA-MB-231 and MCF-7 cells was detected by fluorescent microscopy following DAPI staining (magnification, ×400). The histogram represents the apoptotic rate. (D) Analysis of apoptotic cells induced by HM for 24 h using flow cytometry. The histogram represents the apoptotic rates. Data are presented as the mean ± SD from three independent experiments. *P<0.05 and **P<0.01, with comparisons indicated by brackets. HM, harmine.

HM decreases the expression level of TAZ in MDA-MB-231 and MCF-7 cells

Increasing studies have suggested that TAZ is an oncogene in human cancer cells and serves an important role in the development of tumors (17). It has been reported that TAZ is expressed at high levels in breast cancer cell lines, promotes cell proliferation, migration and tumorigenesis, and inhibits apoptosis in breast cancer (29,30,34). To further understand the mechanism underlying the anticancer activities induced by HM, the present study examined whether TAZ was involved in the anticancer mechanism. The relative mRNA expression of TAZ was significantly decreased, compared with that in the control group (Fig. 3A). Following 48 h of HM treatment (50, 100 or 150 μM), the protein expression of TAZ was reduced in the MDA-MB-231 and MCF-7 cells. The activation of MAPK kinase/ERK and PI3K/AKT has been reported to regulate cancer cell proliferation and migration through various pathways (36,37). In the present study, proliferation- and migration-related proteins, including p-Erk and p-Akt, were decreased, whereas anti-apoptotic protein Bcl-2 was decreased and pro-apoptotic Bax was increased (Fig. 3B).

Figure 3 HM mediates antitumor effects via the downregulation of TAZ in MDA-MB-231 and MCF-7 cells. (A) MDA-MB-231 and MCF-7 cells were treated with HM (50, 100 or 150 μM) for 24 h and the relative mRNA transcription levels were determined via reverse transcription-quantitative polymerase chain reaction analysis. (B) MDA-MB-231 and MCF-7 cells were treated with HM (50, 100 or 150 μM) for 48 h, and the expression of proliferation, migration and apoptosis-related proteins, Akt, p-Akt, Erk, p-Erk, Bcl-2 and Bax, were detected by western blotting. β-actin was used as an internal standard. Data are presented as the mean ± SD of three independent experiments. *P<0.05 and **P<0.01 vs. 0 μM. HM, harmine; TAZ, transcriptional co-activator with PDZ-binding motif; Akt, protein kinase B; Erk, extracellular signal-regulated kinase; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; p-, phosphorylated.

Overexpression of TAZ inhibits the anticancer activity of HM

In order to validate that HM-induced anticancer activity via targeting TAZ, the effect of increased TAZ on HM-mediated anticancer activity was measured. The MDA-MB-231 and MCF-7 cells were transfected with either a TAZ-expressing plasmid (pCMV6-TAZ) or a control plasmid (pCMV6-control). At 2 days post-transfection, western blotting was performed to check the transfection efficiency of TAZ, the expression of TAZ was increased in the TAZ overexpression group (Fig. 4A). The expression level of TAZ in the TAZ overexpression group under HM treatment (50, 100 or 150 μM) was decreased in a dose-dependent manner (Fig. 4B). The transfected cells were treated with HM (50, 100 or 150 μM) for 48 h. When compared with negative control cells, the overexpression of TAZ in breast cancer cells was found to prevent the HM-induced inhibition of cell proliferation and migration (Fig. 4C and D). HM-induced cell apoptosis was also inhibited by the overexpression of TAZ (Fig. 4E).

Figure 4 Overexpression of TAZ inhibits the anticancer activities of HM. (A) Transfection efficiency of TAZ in MDA-MB-231 and MCF-7 cells was determined by western blotting. (B) Western blotting results of the TAZ-overexpression groups under HM treatment (50, 100 and 150 μM). (C) Overexpression of TAZ inhibited the HM-induced inhibition of proliferation. (D) Overexpression of TAZ inhibited the HM-induced inhibition of migration activity. (E) Overexpression of TAZ inhibited HM-induced apoptosis. Data are presented as the mean ± SD of three independent experiments. *P<0.05 and **P<0.01 vs. NC. TAZ, transcriptional co-activator with PDZ-binding motif; HM, harmine; NC, negative control (pCMV6-control).

HM inhibits the growth of breast xenograft tumors in vivo

The MCF-7 cells were subcutaneously injected into athymic nude mice to establish a breast xenograft tumor model, and tumor growth was recorded. Different doses of HM (20, 40 or 80 mg/kg/day) were administered, and HM was shown to reduce tumor volume and weight in a dose- and time- dependent manner (Fig. 5A-D). Tumor tissues were used to evaluate the level of TAZ by IHC, RT-qPCR and western blot analyses. It was found that HM decreased the level of TAZ, compared with that in the control group (Fig. 5E-G). The IHC results showed that the proliferation and expression of metastasis-related proteins, including p-Akt and p-Erk, were decreased compared with the control group (Fig. 5H). These results indicated that HM inhibited the development of breast cancer in vivo.

Figure 5 HM inhibits breast cancer tumor growth in vivo. (A) Mice were sacrificed 2 weeks after being injected with different doses of HM. (B) Tumors were dissected and images were captured. (C) MCF-7 cells were injected into the nude mice. Tumor volume was measured at 2-day intervals and the growth curves were drafted. (D) Tumors were weighted at the end of treatment. (E) Relative mRNA expression of TAZ in tumor tissues from xenograft mice. (F) Representative images from western blot analysis for TAZ protein expression in tumor tissues from xenograft mice. (G and H) Tumor tissues were analyzed by H&E and immunohistochemistry for TAZ, Bax, Bcl-2, p-Erk and p-Akt. Magnification, ×400. **P<0.01, with comparisons indicated by brackets. HM, harmine; H&E, hematoxylin and eosin; TAZ, transcriptional co-activator with PDZ-binding motif; Akt, protein kinase B; Erk, extracellular signal-regulated kinase; Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associatedX protein; p-, phosphorylated.

Discussion

Although current therapeutic strategies can lead to considerable anticancer activity, the development of novel antitumor agents with less toxicity remains of interest. HM is a natural β-carboline alkaloid isolated from Peganum harmala, which was been previously used in folk medicine as an anticancer therapy (5). Studies have shown the anticancer activities of HM through the activation of apoptosis and autophagy (38); however, the effect of HM targeting TAZ in breast cancer has not been previously reported. The present study demonstrated the anticancer effects of HM on breast cancer and revealed a novel target of HM that is important for its activity.

Previous studies have reported the antitumor effects of HM on hepatocellular carcinoma (39), gastric cancer (9) and neuroblastoma (40). In the present study, the anticancer activity of HM was demonstrated using MDA-MB-231 and MCF-7 cells in vitro and MCF-7 cell-derived xenograft tumor in vivo. In vitro, HM was found to inhibit proliferation and migration in a dose- and time- dependent manner. Consistent with this result, it was observed that HM significantly increased cell apoptosis. Following treatment with HM, cellular morphological changes, including cell rounding, shrinkage and karyopyknosis, were observed. In vivo, HM also inhibited tumor growth, in terms of tumor volume and weight, in a dose-dependent manner. These results suggest that HM may be used in combination with other chemical drugs for the inhibition of breast cancer growth and metastasis.

To reveal the underlying molecular mechanism through which HM induces anticancer activity in human breast cancer, the expression of TAZ was investigated following HM treatment. The Hippo pathway serves an important role in mammalian developmental stages (41-44). TAO1-3, mammalian Ste20-like kinase 1/2, MAPK kinase kinase kinase 1-4/6/7, large tumor suppressor 1/2 and nuclear Dbf2-related 1/2 are the core kinases, whereas yes-associated protein (YAP) and TAZ are the primary downstream effectors of the Hippo pathway in mammals. When phosphorylated by these core kinases, YAP is sequestered and degraded in the cytoplasm (45). The Hippo pathway coordinates cell proliferation and apoptosis in response to a variety of signals by regulating the transcriptional coactivators YAP and TAZ (46). Although it has been reported that YAP functions as a tumor suppressor in breast cancer (47), it has been described that TAZ is an oncogenic protein in certain types of human cancer, including non-small cell lung and breast cancer (26,34). It was also found in the present study that the level of TAZ was decreased in vitro following treatment with HM, and that the expression of TAZ was reduced in the MCF-7 xenograft tumor. These results revealed that HM may function by targeting TAZ. To further verify this, experiments were performed to reveal that the antiproliferative and pro-apoptotic activities of HM were inhibited by overexpressing TAZ.

Furthermore, several growth factors associated with proliferation and metabolism were examined in HM-treated MDA-MB-231 and MCF-7 cells. The PI3K/Akt pathway is commonly recognized for its critical role in autophagy (48), metabolism (49) and metastasis (50). The elevated phosphory-lation of Akt led to higher tumor recurrence and poorer overall survival (51). Erk belongs to a subclass of MAPKs that includes serine/threonine kinases. Upon activation of the MAPK pathway, Erk is phosphorylated and regulates various cellular processes, including proliferation, differentiation, apoptosis and transformation (52). In the present study, it was found that HM treatment increased the levels of p-Akt and p-Erk in vitro and in vivo. The Bcl-2 family of proteins is divided into two subfamilies; Bcl-2 and Bcl-xl are anti-apoptotic proteins, whereas Bax, Bad and Bid are pro-apoptotic proteins (53). The results of the present study indicated a decreased level of Bcl-2 and increased level of Bax in HM-treated cells, which is consistent with the immunohistochemical results obtained from the MCF-7 xenograft tumor. All the above results confirmed the antiproliferative and pro-apoptotic function of HM on breast cancer.

In conclusion, the present study demonstrated the anticancer (antiproliferative, antimetastatic and pro-apoptotic) activity of HM on breast cancer cell lines. The study also identified a novel target of HM, TAZ, in antagonizing the role of HM on breast cancer cell lines, however, the anticancer molecular mechanisms of HM require further in-depth investigation. Therefore, HM may serve as an anticancer agent in the chemoprevention and treatment of breast cancer, although future clinical and pharmacological studies are required to confirm this.

Supplementary Materials

Funding

This study was partially sponsored by the National Natural Science Foundation of China (grant no. 81301084 to CP; grant no. 81800296 to SC), the Natural Science Foundation of Hubei Province in China (grant no. 2017CFB357 to SC) and the Health Commission Foundation of Hubei Province in China (grant no. WJ2019M029 to JHu).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

SC, CP, YD, JHe and JHu conceived and designed the experiments. YD, JHe, TZ and GY performed the experiments. XS and TY analyzed data. YD and JHe wrote the manuscript.

Ethics approval and consent to participate

Animal studies were approved by the Committee on the Ethics of Animal Experiments of the Tongji Medical College, Huazhong University of Science and Technology (IACUC no. 837).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations:

Acknowledgments

The authors would like to thank Mrs. Weiqun Chen (Central Laboratory, The Central Hospital of Wuhan) for kindly providing technical assistance in cell experiments and Mr. Shunchang Zhou (Department of Experimental Zoology, Tongji Medical College) for animal care.

References